Brain Tumor Drugs Market
Brain Tumor Drugs Market by Therapy, Indication, Distribution Channel & Region | Forecast 2023 to 2033
Rising Prevalence of Brain Tumors among the Older Population due to Stress and Exposure to Electromagnetic Radiation, Drive the Market Growth. Around 30+ Nations with Significant Investment Prospects are at the Center of FMI's Insight.
Brain Tumor Drugs Market Outlook (2023 to 2033)
The brain tumor drugs market is estimated to record a 9.2% CAGR from 2023 to 2033. The market is likely to reach US$ 2.65 billion in 2023 and is expected to be worth US$ 6.30 billion in 2033.
| Report Attribute | Details |
|---|---|
| Brain Tumor Drugs Market Value (2023) | US$ 2.65 billion |
| Brain Tumor Drugs Market Anticipated Value (2033) | US$ 6.30 billion |
| Brain Tumor Drugs Market Growth Rate (2023 to 2033) | 9.2% CAGR |
Surging Neurological Condition to Increase the Demand
Rising awareness of neurological illnesses in children and adults is boosting the brain tumor drugs market. Brain illnesses, which include several neurodegenerative, psychiatric, and developmental problems, are the reasons for death associated with brain damage worldwide. According to the American Medical Association (AMA), more than 20% of the world's population is expected to be 65 years or older by 2050.
Cancer, a global public health issue, ranks second in the cause of morbidity in the United States. The global elderly population and the emergence of novel diseases are expected to drive growth in the brain tumor medication market.
The brain tumor medication tackles abnormal cell growth in the brain and is administered in combination or alone, depending on their location, shape, and size. For example, Temozolomide, Avastin, and BiCNU carmustine are medications used to treat brain tumors. Government initiatives and increased knowledge about medical breakthroughs are expected to propel the industry growth in the coming years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2017 to 2022 Brain Tumor Drugs Market Outlook in Comparison to 2023 to 2033 Growth Forecast
The brain tumor drugs market was worth US$ 2.52 billion in 2022, at a 9% CAGR from 2017 to 2022.
Developments in medical treatment and advanced patient care for brain illnesses are available globally. Experiments and advancements in combination therapy with current and novel medications have resulted in people suffering from brain tumor problems.
The increased use of targeted therapeutics may restrain market growth. The pharmaceutical industry is focused on developing drugs that specifically target the eradication of cancer cells while causing no harm to normal bodily cells, as some cancer spread to the brain through different body parts. Bevacizumab, for example, prevents cancer cell replication, allowing cytotoxic chemotherapy medications that limit normal cell division to be used. Furthermore, the growing acceptability of these procedures and therapies is anticipated to create roadblocks in the use of traditional brain tumor medications, threatening market expansion.
| Historical CAGR (2017 to 2022) | 9% |
|---|---|
| Forecast CAGR (2023 to 2033) | 9.2% |
- Short Term (2023 to 2026): The increasing prevalence of neurological disorders worldwide is the primary driving factor responsible for the growth of the brain tumor market.
- Medium Term (2026 to 2029): Prolonged life expectancy, increased virus exposure, and sedentary lifestyle, neurological illnesses have been highlighted as one of the most prevalent disorders.
- Long Term (2029 to 2033): Researchers are working on new techniques to diagnose a brain tumor, such as biomarker tests that can estimate a patient’s prognosis.
As per the FMI analysts, a valuation of US$ 6.30 billion by 2033 is estimated for the market.
| Year | Market Value |
|---|---|
| 2016 | US$ 1.43 billion |
| 2021 | US$ 2.23 billion |
| 2022 | US$ 2.52 billion |
| 2023 | US$ 2.65 billion |
| 2033 | US$ 6.30 billion |
Comparative Analysis of Adjacent Markets
Brain Tumor Drugs Market:
| Differentiating Aspects | Brain Tumor Drugs Market |
|---|---|
| Anticipated CAGR (2023 to 2033) | 9.2% |
| Market Valuation (2023) | US$ 2.65 billion |
| Growth Factors | Rising cases of brain cancer |
| Future Opportunities | A robust drug pipeline is in demand |
| Market Trends | Immunotherapy is expected to experience rapid growth |
Brain Tumor Treatment Market:
| Differentiating Aspects | Brain Tumor Treatment Market |
|---|---|
| Anticipated CAGR (2023 to 2033) | 7.4% |
| Market Valuation (2023) | US$ 3,164.19 billion |
| Growth Factors | Rising incidence of brain tumors has increased the necessity for effective therapy |
| Future Opportunities | Increased pharmaceutical R&D spending is likely to fuel the worldwide brain tumor therapy market |
| Market Trends | Due to enormous technological breakthroughs in the healthcare industry, innovative therapies for brain conditions are producing effective outcomes. |
Brain Cancer Therapeutics Market:
| Differentiating Aspects | Brain Cancer Therapeutics Market |
|---|---|
| Anticipated CAGR (2023 to 2033) | 10% |
| Market Valuation (2023) | US$ 3,072.19 billion |
| Growth Factors | Brain and CNS cancer-related death to fuel the brain cancer therapeutics market, globally |
| Future Opportunities | Increasing research and development spending to create new treatment approaches and medical equipment |
| Market Trends | Increased research into new treatments and radiation therapy |
Find your sweet spots for generating winning opportunities in this market.
Increased Incidence of Brain Cancer Cases to Drive Market Growth
Factors such as changing lifestyles and eating choices increased urbanization, and smoking habit is surging the cases of brain conditions among adults and elderly people. According to the WHO, nearly 23.0% of adults used tobacco in 2020. As a result, the increased incidence of smoking among adults contributes to the global increase in cancer cases.Furthermore, as the prevalence of various cancer kinds rises, so does the rate of diagnosis and treatment. For example, according to GLOBOCAN, roughly 19,300,000 persons worldwide were diagnosed with cancer in 2020.
Brain tumors account for around 1% to 2% of cancer death in the United States, with a significant fatality rate. The increased occurrence of brain tumors is due to factors such as strong radiation exposure that causes DNA to change and eventually lead to cancer.
Research and Development Pipeline for Novel Treatments
The rising prevalence of brain cancer and rising diagnosis rates, particularly in industrialized nations, are creating a pool of patients in need of treatment. This, together with market participants' increased focus on research and development activities to introduce new medications with clinical benefits for the treatment and management of the illness, is propelling the brain tumor pharmaceuticals market forward.
Unmet needs, such as the availability of these medications on the market, associated with the various stages of brain cancer management, may aid in shifting research and development priorities and improving physicians' therapeutic approaches. As a result, many pharmaceutical companies are investing in research and development to find novel medications for the treatment of brain tumors.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
High Treatment Costs along with Limited Reimbursement, are expected to Slow Market Growth
Several side effects associated with brain tumor treatments, as well as the high costs of these drugs, are a few reasons restricting market expansion. Furthermore, lower brain tumor diagnosis and treatment rates, as well as limited reimbursement for these medications in underdeveloped countries, are projected to restrain market growth.
Brain cancer diagnosis and treatment rates are substantially lower in emerging countries than in developed countries. In China, for example, the prevalence of brain tumors was 14.82 per 100,000 individuals in 2021.
Advancement in Brain Tumor Diagnosis to Support Market Growth
Early detection and treatment of brain tumors are difficult due to variables such as the body's blood-brain barrier, which normally protects the spinal cord and brain from harmful substances. This barrier, however, also keeps many forms of chemotherapy out. Thus, improved methods for brain tumor diagnosis and treatment are required. The prevalence of brain tumors is steadily growing, which can be ascribed to advancements in detection and treatment procedures.
Prognostic indicators are vital in the creation of tailored medications and in increasing the survival rate of persons with brain tumors. Neurological and neuroimaging studies are utilized to diagnose glioma at an advanced stage. Assessment of genetic characteristics in biopsy specimens of brain tumor patients is one of the important tools for improved diagnosis and treatment of brain tumors. Furthermore, circulating nucleic acid in the blood and other biological fluids can be employed as a marker for the early detection and treatment of brain tumors.
Success Rates of Immunotherapy May Drive Market Growth
Immunotherapy is a cancer treatment that aids the immune system in its battle against cancer. Immunotherapies are employed in a range of cancer treatments. Immunotherapy holds promise for treating brain cancer, which has traditionally been treated with chemotherapy, radiation therapy, and surgery. Immunotherapy, often known as biological treatment, uses living organisms to treat disease.
Vaccines are a promising new type of immunotherapy that boosts the immune system's ability to fight cancer. This market's growth is expected to be fueled by novel immunotherapy treatments for brain cancer. Furthermore, there are numerous authorized immunotherapies for various brain malignancies, and industry companies and universities are heavily working on researching and marketing new brain tumor immunotherapies.
As a result, this market may grow as universities increase their efforts to develop novel immunotherapy treatments. As a result, the aforementioned factors have contributed to the market's overall expansion.
Market is likely to be Dominated by North America
The North American brain tumor market is expected to grow significantly during the forecast period. The United States is expected to lead the market because of its developed healthcare industry and increased awareness of sophisticated technologies among the populace in this area.
According to the American Brain Tumor Association, about 84,000 people were diagnosed with a primary brain tumor in 2021, and roughly 18,000 died as a result of a primary malignant brain tumor. Furthermore, more than 28,000 youngsters in the United States were diagnosed with a brain tumor in 2021, according to the same source.
The increased occurrence of brain tumors is likely to boost regional growth. Furthermore, the market analyzed in the United States is projected to be driven by regular product releases and pharmacological approvals, as well as considerable R&D initiatives for the treatment of brain tumors.
The surging clinical trials for brain tumor therapy in the United States are likely to boost the expansion of this market. As a result of the foregoing factors, the North American brain tumor drugs market is expected to expand significantly over the forecast period.
The market in Latin America is expanding due to an increase in brain tumor diagnosis and treatment, which has created a demand for these medications in the region. This, combined with the introduction of new pharmaceuticals in the region, is contributing to the region's market growth.
Common CNS Cancer in Europe Boosts the Market
The frequency of primary brain tumors, favorable regulatory circumstances in leading European nations, and an increased emphasis on research activities for producing brain tumor drugs are driving the market in Europe.
According to national and regional estimates, around US$ 115.00 billion was spent on cancer care in Europe in 2019, with direct expenditures on cancer medications accounting for nearly US$ 35.00 to US$ 40.00 billion.
Market in Asia Pacific is expected to Accelerate due to Rising Awareness
The market in the Asia Pacific is influenced by rising awareness of brain cancer, early detection, and increased clinical trial in drug delivery for brain cancer cells. Furthermore, increased knowledge regarding brain tumors and their forms in the region boosts the market growth.
According to brain tumor research, the average rating of brain tumor care in Australia was the lowest of all cancers, with a score of 8.37 out of 10. Moreover, in 2018, nearly two thousand people died due to brain cancer in the Asia Pacific.
Competitive Landscape
Prominent Participants in the Market
- AstraZeneca plc
- Johnson & Johnson Inc
- Merck & Co
- Pfizer Inc
- F. Hoffmann-La Roche Ltd
- Y-mAbs Therapeutics, Inc
- Shimadzu Corporation
- Bristol-Myers Squibb
- Bayer AG
- Dr. Reddy's Laboratories Ltd
- Among others
Scope of Report
| Attribute | Details |
|---|---|
| Market Size Value in 2023 | US$ 2.65 billion |
| Market Size Value in 2033 | US$ 6.30 billion |
| Market Analysis | US$ billion for Value |
| Key Region Covered |
|
| Key Segments |
|
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
Key Segment
By Therapy:
- Targeted Therapy
- Chemotherapy
- Immunotherapy
- Others
By Indication:
- Pituitary
- Meningioma
- Glioma
- Others
By Distribution Channel:
- Hospital Pharmacy
- Retail & Online Pharmacy
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- The Middle East and Africa
Frequently Asked Questions
What is the Key Driver of the Brain Tumor Drugs Market?
Surging neurological condition is the key driver of the market.
Which Factor is Restraining the Market Growth?
The increased use of targeted therapeutics may restrain the market growth.
What will be the Growth Rate until 2033?
The market is likely to experience a 9.2% CAGR until 2033.
What is the Estimated Market Value in 2033?
The market is predicted to be worth US$ 6.30 billion in 2033.
Which Region will Dominate the Market?
North America is likely to dominate the market.
Table of Content
1. Executive Summary | Brain Tumor Drugs Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Temozolomide 5.3.2. Carmustine 5.3.3. Cisplatin 5.3.4. Bevacizumab 5.3.5. Geftinib 5.3.6. Erlotinib 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2023 to 2033 6.3.1. Targeted Therapy 6.3.2. Chemotherapy 6.3.3. Immunotherapy 6.4. Y-o-Y Growth Trend Analysis By Therapy, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Therapy, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Indication , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication , 2023 to 2033 7.3.1. Pituitary Tumor 7.3.2. Meningioma 7.3.3. Glioblastoma 7.4. Y-o-Y Growth Trend Analysis By Indication , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Indication , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.3.3. Online Pharmacies 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. South Asia 9.3.5. East Asia 9.3.6. Oceania 9.3.7. MEA 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. USA 10.2.1.2. Canada 10.2.2. By Drug Class 10.2.3. By Therapy 10.2.4. By Indication 10.2.5. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Therapy 10.3.4. By Indication 10.3.5. By Distribution Channel 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Drug Class 11.2.3. By Therapy 11.2.4. By Indication 11.2.5. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Therapy 11.3.4. By Indication 11.3.5. By Distribution Channel 11.4. Key Takeaways 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. United kingdom 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Drug Class 12.2.3. By Therapy 12.2.4. By Indication 12.2.5. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Therapy 12.3.4. By Indication 12.3.5. By Distribution Channel 12.4. Key Takeaways 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Rest of South Asia 13.2.2. By Drug Class 13.2.3. By Therapy 13.2.4. By Indication 13.2.5. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Therapy 13.3.4. By Indication 13.3.5. By Distribution Channel 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug Class 14.2.3. By Therapy 14.2.4. By Indication 14.2.5. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Therapy 14.3.4. By Indication 14.3.5. By Distribution Channel 14.4. Key Takeaways 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. Australia 15.2.1.2. New Zealand 15.2.2. By Drug Class 15.2.3. By Therapy 15.2.4. By Indication 15.2.5. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Therapy 15.3.4. By Indication 15.3.5. By Distribution Channel 15.4. Key Takeaways 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Drug Class 16.2.3. By Therapy 16.2.4. By Indication 16.2.5. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Drug Class 16.3.3. By Therapy 16.3.4. By Indication 16.3.5. By Distribution Channel 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Drug Class 17.1.2.2. By Therapy 17.1.2.3. By Indication 17.1.2.4. By Distribution Channel 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Drug Class 17.2.2.2. By Therapy 17.2.2.3. By Indication 17.2.2.4. By Distribution Channel 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Drug Class 17.3.2.2. By Therapy 17.3.2.3. By Indication 17.3.2.4. By Distribution Channel 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Drug Class 17.4.2.2. By Therapy 17.4.2.3. By Indication 17.4.2.4. By Distribution Channel 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Drug Class 17.5.2.2. By Therapy 17.5.2.3. By Indication 17.5.2.4. By Distribution Channel 17.6. United kingdom 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Drug Class 17.6.2.2. By Therapy 17.6.2.3. By Indication 17.6.2.4. By Distribution Channel 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Drug Class 17.7.2.2. By Therapy 17.7.2.3. By Indication 17.7.2.4. By Distribution Channel 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Drug Class 17.8.2.2. By Therapy 17.8.2.3. By Indication 17.8.2.4. By Distribution Channel 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Drug Class 17.9.2.2. By Therapy 17.9.2.3. By Indication 17.9.2.4. By Distribution Channel 17.10. India 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Drug Class 17.10.2.2. By Therapy 17.10.2.3. By Indication 17.10.2.4. By Distribution Channel 17.11. Malaysia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Drug Class 17.11.2.2. By Therapy 17.11.2.3. By Indication 17.11.2.4. By Distribution Channel 17.12. Singapore 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Drug Class 17.12.2.2. By Therapy 17.12.2.3. By Indication 17.12.2.4. By Distribution Channel 17.13. Thailand 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Drug Class 17.13.2.2. By Therapy 17.13.2.3. By Indication 17.13.2.4. By Distribution Channel 17.14. China 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Drug Class 17.14.2.2. By Therapy 17.14.2.3. By Indication 17.14.2.4. By Distribution Channel 17.15. Japan 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Drug Class 17.15.2.2. By Therapy 17.15.2.3. By Indication 17.15.2.4. By Distribution Channel 17.16. South Korea 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Drug Class 17.16.2.2. By Therapy 17.16.2.3. By Indication 17.16.2.4. By Distribution Channel 17.17. Australia 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Drug Class 17.17.2.2. By Therapy 17.17.2.3. By Indication 17.17.2.4. By Distribution Channel 17.18. New Zealand 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Drug Class 17.18.2.2. By Therapy 17.18.2.3. By Indication 17.18.2.4. By Distribution Channel 17.19. GCC Countries 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Drug Class 17.19.2.2. By Therapy 17.19.2.3. By Indication 17.19.2.4. By Distribution Channel 17.20. South Africa 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Drug Class 17.20.2.2. By Therapy 17.20.2.3. By Indication 17.20.2.4. By Distribution Channel 17.21. Israel 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Drug Class 17.21.2.2. By Therapy 17.21.2.3. By Indication 17.21.2.4. By Distribution Channel 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Drug Class 18.3.3. By Therapy 18.3.4. By Indication 18.3.5. By Distribution Channel 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Genetech USAA 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Bristol Myers Squibb 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Hoffmann- La Roche 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. AstraZeneca Plc. 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Pfizer Inc. 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. Novartis AG 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Antisense Pharma 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Merck & Co 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. MacLeod’s Pharmaceutical Limited 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Mankind Pharma 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 19.1.11. Siemens Healthineers AG 19.1.11.1. Overview 19.1.11.2. Product Portfolio 19.1.11.3. Profitability by Market Segments 19.1.11.4. Sales Footprint 19.1.11.5. Strategy Overview 19.1.11.5.1. Marketing Strategy 19.1.12. Dr. Reddy’s Laboratories Ltd. 19.1.12.1. Overview 19.1.12.2. Product Portfolio 19.1.12.3. Profitability by Market Segments 19.1.12.4. Sales Footprint 19.1.12.5. Strategy Overview 19.1.12.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by Indication , 2018 to 2033 Table 5: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 9: North America Market Value (US$ Million) Forecast by Indication , 2018 to 2033 Table 10: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 13: Latin America Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 14: Latin America Market Value (US$ Million) Forecast by Indication , 2018 to 2033 Table 15: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 16: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 18: Europe Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 19: Europe Market Value (US$ Million) Forecast by Indication , 2018 to 2033 Table 20: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 21: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 23: South Asia Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 24: South Asia Market Value (US$ Million) Forecast by Indication , 2018 to 2033 Table 25: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 26: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 27: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 28: East Asia Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 29: East Asia Market Value (US$ Million) Forecast by Indication , 2018 to 2033 Table 30: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 31: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 32: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 33: Oceania Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 34: Oceania Market Value (US$ Million) Forecast by Indication , 2018 to 2033 Table 35: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 36: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 37: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 38: MEA Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 39: MEA Market Value (US$ Million) Forecast by Indication , 2018 to 2033 Table 40: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Indication , 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 6: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 9: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 12: Global Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 13: Global Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 14: Global Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 15: Global Market Value (US$ Million) Analysis by Indication , 2018 to 2033 Figure 16: Global Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033 Figure 17: Global Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033 Figure 18: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 21: Global Market Attractiveness by Drug Class, 2023 to 2033 Figure 22: Global Market Attractiveness by Therapy, 2023 to 2033 Figure 23: Global Market Attractiveness by Indication , 2023 to 2033 Figure 24: Global Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 25: Global Market Attractiveness by Region, 2023 to 2033 Figure 26: North America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 27: North America Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 28: North America Market Value (US$ Million) by Indication , 2023 to 2033 Figure 29: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 30: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 37: North America Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 38: North America Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 39: North America Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 40: North America Market Value (US$ Million) Analysis by Indication , 2018 to 2033 Figure 41: North America Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033 Figure 42: North America Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033 Figure 43: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 46: North America Market Attractiveness by Drug Class, 2023 to 2033 Figure 47: North America Market Attractiveness by Therapy, 2023 to 2033 Figure 48: North America Market Attractiveness by Indication , 2023 to 2033 Figure 49: North America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 50: North America Market Attractiveness by Country, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 52: Latin America Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 53: Latin America Market Value (US$ Million) by Indication , 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 55: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 59: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 60: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 62: Latin America Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 63: Latin America Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 65: Latin America Market Value (US$ Million) Analysis by Indication , 2018 to 2033 Figure 66: Latin America Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033 Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033 Figure 68: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 71: Latin America Market Attractiveness by Drug Class, 2023 to 2033 Figure 72: Latin America Market Attractiveness by Therapy, 2023 to 2033 Figure 73: Latin America Market Attractiveness by Indication , 2023 to 2033 Figure 74: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 76: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 77: Europe Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 78: Europe Market Value (US$ Million) by Indication , 2023 to 2033 Figure 79: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 80: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 81: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 84: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 85: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 86: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 87: Europe Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 88: Europe Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 89: Europe Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 90: Europe Market Value (US$ Million) Analysis by Indication , 2018 to 2033 Figure 91: Europe Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033 Figure 92: Europe Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033 Figure 93: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 94: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 95: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 96: Europe Market Attractiveness by Drug Class, 2023 to 2033 Figure 97: Europe Market Attractiveness by Therapy, 2023 to 2033 Figure 98: Europe Market Attractiveness by Indication , 2023 to 2033 Figure 99: Europe Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 100: Europe Market Attractiveness by Country, 2023 to 2033 Figure 101: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 102: South Asia Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 103: South Asia Market Value (US$ Million) by Indication , 2023 to 2033 Figure 104: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 105: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 106: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 107: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 108: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 109: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 110: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 111: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 112: South Asia Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 113: South Asia Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 114: South Asia Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 115: South Asia Market Value (US$ Million) Analysis by Indication , 2018 to 2033 Figure 116: South Asia Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033 Figure 117: South Asia Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033 Figure 118: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 119: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 120: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 121: South Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 122: South Asia Market Attractiveness by Therapy, 2023 to 2033 Figure 123: South Asia Market Attractiveness by Indication , 2023 to 2033 Figure 124: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 125: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 126: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 127: East Asia Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 128: East Asia Market Value (US$ Million) by Indication , 2023 to 2033 Figure 129: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 130: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 131: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 132: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 134: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 135: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 137: East Asia Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 138: East Asia Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 139: East Asia Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 140: East Asia Market Value (US$ Million) Analysis by Indication , 2018 to 2033 Figure 141: East Asia Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033 Figure 142: East Asia Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033 Figure 143: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 144: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 145: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 146: East Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 147: East Asia Market Attractiveness by Therapy, 2023 to 2033 Figure 148: East Asia Market Attractiveness by Indication , 2023 to 2033 Figure 149: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 150: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 151: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 152: Oceania Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 153: Oceania Market Value (US$ Million) by Indication , 2023 to 2033 Figure 154: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 155: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 156: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 157: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 158: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 159: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 160: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 161: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 162: Oceania Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 163: Oceania Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 164: Oceania Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 165: Oceania Market Value (US$ Million) Analysis by Indication , 2018 to 2033 Figure 166: Oceania Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033 Figure 167: Oceania Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033 Figure 168: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 169: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 170: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 171: Oceania Market Attractiveness by Drug Class, 2023 to 2033 Figure 172: Oceania Market Attractiveness by Therapy, 2023 to 2033 Figure 173: Oceania Market Attractiveness by Indication , 2023 to 2033 Figure 174: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 175: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 176: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 177: MEA Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 178: MEA Market Value (US$ Million) by Indication , 2023 to 2033 Figure 179: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 180: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 181: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 184: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 185: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 186: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 187: MEA Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 188: MEA Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 189: MEA Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 190: MEA Market Value (US$ Million) Analysis by Indication , 2018 to 2033 Figure 191: MEA Market Value Share (%) and BPS Analysis by Indication , 2023 to 2033 Figure 192: MEA Market Y-o-Y Growth (%) Projections by Indication , 2023 to 2033 Figure 193: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 194: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 195: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 196: MEA Market Attractiveness by Drug Class, 2023 to 2033 Figure 197: MEA Market Attractiveness by Therapy, 2023 to 2033 Figure 198: MEA Market Attractiveness by Indication , 2023 to 2033 Figure 199: MEA Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 200: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports
